Literature DB >> 20656924

Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection.

Julia M Sugalski1, Benigno Rodriguez, Susan Moir, Donald D Anthony.   

Abstract

Chronic hepatitis C virus (HCV) infection is associated with B cell activation, although underlying mechanisms are unclear. To investigate B cell regulation during HCV infection, we measured bulk B cell CpG and Staphylococcus aureus Cowan-induced IgG Ab-secreting cell (ASC) frequency, HCV and tetanus-specific ASC frequency, BCR- and CD40L-dependent CD80/CD86 expression, and activation of memory CD4 cells. Immature transitional, naive, resting memory, mature activated, tissue-like memory, and plasma B cell subset frequencies, cell cycling, and intrinsic apoptosis were quantified. We observed intact or enhanced tetanus-specific and total IgG ASC frequency, serum IgG, BCR- and CD40L-dependent CD80/CD86 expression, and CD40L-dependent bulk B cell activation of memory CD4 cells in HCV infection. HCV-specific ASCs were observed in HCV-infected but not control subjects, although frequencies were lower compared with tetanus-specific cells. Immature transitional and mature activated B cell subset frequencies were increased in HCV-infected subjects, with immature transitional frequency associated with liver inflammation and serum B cell-activating factor. Mature activated B cells less commonly expressed Ki67, more commonly expressed Bcl2, and were more intrinsically resistant to apoptosis, whereas immature transitional B cells more commonly expressed Ki67, the latter associated with plasma HCV level. Taken together, these results indicate that in the setting of chronic HCV infection, a state of activation results in B cell subset skewing that is likely the result of alterations in homeostasis, cell cycling, and intrinsic resistance to apoptosis and that results in an overall intact or enhanced B cell response to BCR and CD40L.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656924      PMCID: PMC3805966          DOI: 10.4049/jimmunol.1000879

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.

Authors:  Kehmia Titanji; Angelo De Milito; Alberto Cagigi; Rigmor Thorstensson; Sven Grützmeier; Ann Atlas; Bo Hejdeman; Frank P Kroon; Lucia Lopalco; Anna Nilsson; Francesca Chiodi
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

Review 2.  Autoantibodies and common viral illnesses.

Authors:  K E Hansen; J Arnason; A J Bridges
Journal:  Semin Arthritis Rheum       Date:  1998-04       Impact factor: 5.532

3.  Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.

Authors:  Domenico Rosa; Giulietta Saletti; Ennio De Gregorio; Francesca Zorat; Consuelo Comar; Ugo D'Oro; Sandra Nuti; Michael Houghton; Vincenzo Barnaba; Gabriele Pozzato; Sergio Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

4.  Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules.

Authors:  Vito Racanelli; Maria Antonia Frassanito; Patrizia Leone; Maria Galiano; Valli De Re; Franco Silvestris; Franco Dammacco
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity.

Authors:  Amanda K Cuss; Danielle T Avery; Jennifer L Cannons; Li Jun Yu; Kim E Nichols; Peter J Shaw; Stuart G Tangye
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

6.  Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

Authors:  P Cacoub; T Poynard; P Ghillani; F Charlotte; M Olivi; J C Piette; P Opolon
Journal:  Arthritis Rheum       Date:  1999-10

7.  Identification and characterization of circulating human transitional B cells.

Authors:  Gary P Sims; Rachel Ettinger; Yuko Shirota; Cheryl H Yarboro; Gabor G Illei; Peter E Lipsky
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

8.  Effect of hepatitis C virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three year follow-up study.

Authors:  Natalia Soriano-Sarabia; Manuel Leal; Carmen Delgado; Sonia Molina-Pinelo; Beatriz De Felipe; Ezequiel Ruiz-Mateos; Armando Sánchez-Quijano; Eduardo Lissen; Alejandro Vallejo
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

9.  Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients.

Authors:  D Buskila; A Shnaider; L Neumann; M Lorber; D Zilberman; N Hilzenrat; O J Kuperman; E Sikuler
Journal:  Semin Arthritis Rheum       Date:  1998-10       Impact factor: 5.532

10.  Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7.

Authors:  Angela Malaspina; Susan Moir; Jason Ho; Wei Wang; Melissa L Howell; Marie A O'Shea; Gregg A Roby; Catherine A Rehm; Joann M Mican; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

View more
  30 in total

1.  Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.

Authors:  Hiroyoshi Doi; Tara K Iyer; Erica Carpenter; Hong Li; Kyong-Mi Chang; Robert H Vonderheide; David E Kaplan
Journal:  Hepatology       Date:  2012-01-19       Impact factor: 17.425

Review 2.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

Review 3.  Premature B-cell senescence as a consequence of chronic immune activation.

Authors:  Paolo Palma; Stefano Rinaldi; Nicola Cotugno; Veronica Santilli; Savita Pahwa; Paolo Rossi; Alberto Cagigi
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

5.  Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Authors:  Maude Boisvert; Wanrui Zhang; Elizabeth J Elrod; Nicole F Bernard; Jean-Pierre Villeneuve; Julie Bruneau; Joseph Marcotrigiano; Naglaa H Shoukry; Arash Grakoui
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

6.  Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection.

Authors:  Fanyun Kong; Bo Feng; Henghui Zhang; Huiying Rao; Jianghua Wang; Xu Cong; Lai Wei
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

7.  B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis.

Authors:  Lauren E Holz; Joo Chun Yoon; Sukanya Raghuraman; Susan Moir; Michael C Sneller; Barbara Rehermann
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

Review 8.  The Plasticity of Newly Formed B Cells.

Authors:  Natalia V Giltiay; Daniela Giordano; Edward A Clark
Journal:  J Immunol       Date:  2019-12-15       Impact factor: 5.422

9.  Peripheral CD27-CD21- B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis.

Authors:  Hiroyoshi Doi; Shiroh Tanoue; David E Kaplan
Journal:  Clin Immunol       Date:  2013-12-17       Impact factor: 3.969

10.  IL28B genotype and the expression of ISGs in normal liver.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Y Wan
Journal:  Liver Int       Date:  2013-03-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.